Integrative discovery and targeted proteomics elucidate the plasma exosomal landscape in thyroid disorders, with emphasis on papillary thyroid carcinoma complicating Hashimoto’s thyroiditis - Takeaways - MDSpire

Integrative discovery and targeted proteomics elucidate the plasma exosomal landscape in thyroid disorders, with emphasis on papillary thyroid carcinoma complicating Hashimoto’s thyroiditis

  • By

  • Yawei Zhang

  • Xiaolong Ma

  • Wenjing Shi

  • Tianyi Dong

  • Zhen Wang

  • Mao Ding

  • Xingchen Shang

  • Xingsong Tian

  • May 25, 2026

  • 0 min

Share

  • 1

    Papillary thyroid carcinoma (PTC) accounts for approximately 90% of thyroid cancer cases, with Hashimoto's thyroiditis (HT) as a common associated condition.

  • 2

    The study identified 45 differentially expressed proteins (DEPs) in plasma exosomes from patients with PTC associated with HT compared to those with HT alone.

  • 3

    Functional analyses indicated that DEPs were mainly involved in extracellular matrix interactions and immune response pathways.

  • 4

    SVEP1 and IGKV3-7 were validated as significant plasma exosomal biomarkers for PTC in patients with HT, offering insights into disease progression.

  • 5

    The findings suggest the potential for non-invasive clinical diagnosis of PTC in patients with HT through the analysis of plasma exosomal proteins.

Original Source(s)

Integrative discovery and targeted proteomics elucidate the plasma exosomal landscape in thyroid disorders, with emphasis on papillary thyroid carcinoma complicating Hashimoto’s thyroiditis

  • by Yawei Zhang, Xiaolong Ma, Wenjing Shi, Tianyi Dong, Zhen Wang, Mao Ding, Xingchen Shang, Xingsong Tian

  • May 25, 2026

Related Content

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy